Mutagenesis

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 

Retrieved on: 
Monday, April 8, 2024
Principal, Malignancy, Risk, Patient, Food and Drug Administration, City, CRS, NHL, Mutagenesis, Therapy, Hematology, Bone marrow, B-cell lymphoma, APOLLO, Neurotoxicity, DLBCL, Cytokine release syndrome, Lymphoma, Press release

HOUSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada (April 2-7, 2024). Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.

Key Points: 
  • Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.
  • During the presentation, Dr. Shouse showed that this study participant remains in CR nine months following initial treatment with MT-601.
  • This APOLLO participant had diffuse large B cell lymphoma (DLBCL) and failed four prior lines of therapy, including anti-CD19 CAR T cell therapy.
  • Dr. Shouse’s presentation included data from two additional study participants that have been treated at City of Hope.

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Penetrance, HER2, Mutagenesis, EGFR, Cell, Patient, CNS, Cancer, ENU, Human, Senior, TRK, AACR, Crizotinib, ROS1, Drug discovery, Vaccine

CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new preclinical data for its novel HER2-selective inhibitor, NVL-330, and novel ROS1-selective inhibitor, zidesamtinib (NVL-520). The two posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 5 – 10 in San Diego. The posters will also be available on the Nuvalent website at www.nuvalent.com following the presentations.

Key Points: 
  • The two posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 5 – 10 in San Diego.
  • The posters will also be available on the Nuvalent website at www.nuvalent.com following the presentations.
  • "Today's presentations continue to reinforce the differentiated profiles of our drug candidates," said Henry Pelish, Ph.D., Senior Vice President of Drug Discovery at Nuvalent.
  • These mutagenesis screens provide additional preclinical support for zidesamtinib's potential to drive deep and durable responses for patients with ROS1-driven cancers.

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Retrieved on: 
Monday, January 8, 2024
Baylor University, Baylor College of Medicine, Neoplasm, Risk, Leukapheresis, IND, MRD, DLBCL, FDA, Drug discovery, Service provider, Disease, Trial of the century, PCR, Therapy, Marker, Natural history, ARTEMIS, Vasileiou, Mutagenesis, Pancreatic cancer, Press release, Chong, Growth, HSCT, CD19, Patient, Acute myeloid leukemia, Safety, AML, Bone marrow, Food and Drug Administration, Female, APOLLO, Pharmaceutical industry

HOUSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced a restructuring of its clinical programs and a strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline. In addition, the Company reported a clinical update on the Phase 2 ARTEMIS study investigating MT-401, a multiTAA-specific T cell product, for the treatment of patients with acute myeloid leukemia (AML).

Key Points: 
  • The TACTAL study enrolled patients with Hodgkin’s and non-Hodgkin’s lymphoma and demonstrated clinical safety and efficacy with durable clinical responses for 6 years (Vasileiou et al, J Clin Oncol, 2021).
  • Today, Marker is providing a clinical update on the Phase 2 ARTEMIS clinical study (clinicaltrials.gov identifier: NCT04511130), and the direction it will pursue.
  • “We are encouraged by the clinical observations in patients with MRD in our AML study,” said Juan Vera, M.D., President and CEO of Marker Therapeutics.
  • Marker has secured non-dilutive funding to support the clinical investigation of a ready for use MT-401 product in patients with AML.

Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse

Retrieved on: 
Monday, December 11, 2023
Risk, Principal, DLBCL, FDA, City, Therapy, Press release, B-cell lymphoma, Neurotoxicity, Mutagenesis, Chong, Patient, Lymphoma, Bone marrow, Food and Drug Administration, APOLLO, Pharmaceutical industry

The patient had diffuse large B cell lymphoma (DLBCL) and failed four prior lines of therapy, including anti-CD19 CAR T cell therapy.

Key Points: 
  • The patient had diffuse large B cell lymphoma (DLBCL) and failed four prior lines of therapy, including anti-CD19 CAR T cell therapy.
  • Marker reports today that six months following the initial treatment with MT-601 the study participant has maintained complete response to treatment.
  • “Relapse rates following CAR T cell therapy are high,” said Juan F. Vera, M.D., President and Chief Executive Officer of Marker Therapeutics.
  • “The ongoing complete response observed after MT-601 infusion in a CAR relapsed patient with lymphoma suggests superior durability of our therapy over CAR T cells in this patient.

European Union Notifies Trading Partners on the Proposal for the Regulation of Plants Obtained from New Genomic Techniques

Retrieved on: 
Friday, December 1, 2023
Senior, Policy, European Commission, Council, Gene editing, Natural Resources, CBUS, World Trade Organization, European, European Parliament, NASA Exoplanet Archive, SAN, Legislation, Civil service commission, Plant, Transition, Mutagenesis, Breeding, Commissioner, Nature, NGT

SAN DIEGO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, acknowledges the European Union notification to World Trade Organization (WTO) members on the European Commission proposal for regulation of plants obtained from New Genomic Techniques (NGTs) on 31st October.

Key Points: 
  • SAN DIEGO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, acknowledges the European Union notification to World Trade Organization (WTO) members on the European Commission proposal for regulation of plants obtained from New Genomic Techniques (NGTs) on 31st October.
  • The notification is intended to ensure any potential trade barriers are avoided and invites comments from WTO members by the year end.
  • NGTs include a variety of gene editing techniques leading to genetic changes classed as targeted mutagenesis and cisgenesis.
  • Recent disclosures forecast that Members of the European Parliament are going to vote on the proposal during January 2024.

European Union Notifies Trading Partners on the Proposal for the Regulation of Plants Obtained from New Genomic Techniques

Retrieved on: 
Friday, December 1, 2023
Senior, Policy, European Commission, Council, Gene editing, Natural Resources, CBUS, World Trade Organization, European, European Parliament, NASA Exoplanet Archive, SAN, Legislation, Civil service commission, Plant, Transition, Mutagenesis, Breeding, Commissioner, Nature, NGT

SAN DIEGO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, acknowledges the European Union notification to World Trade Organization (WTO) members on the European Commission proposal for regulation of plants obtained from New Genomic Techniques (NGTs) on 31st October.

Key Points: 
  • SAN DIEGO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, acknowledges the European Union notification to World Trade Organization (WTO) members on the European Commission proposal for regulation of plants obtained from New Genomic Techniques (NGTs) on 31st October.
  • The notification is intended to ensure any potential trade barriers are avoided and invites comments from WTO members by the year end.
  • NGTs include a variety of gene editing techniques leading to genetic changes classed as targeted mutagenesis and cisgenesis.
  • Recent disclosures forecast that Members of the European Parliament are going to vote on the proposal during January 2024.

Global Times: Chinese Gen-Zers aim for journey to the sky with more imaginative innovation propelled by China's modernization process

Retrieved on: 
Tuesday, December 26, 2023
Yuan, International Space Station, Global Times, Imagination, Science, Sand, Tiangong space station, Incubator, Recycling, Astronaut, Seed, Student, School, Physics, International Academy, Nuclear fusion, Hope, Fermentation, Education, Marlin, University, Temperature, Knowledge, Generation Z, Water, Mutagenesis, Breeding, Advertising, Social media, Mozi, Chinese, Communication, Radiation, Policy, Real-time, Tourism

At an altitude of 400,000 meters above the earth, the carefully raised marlins would eventually appear on Taikonauts' dinner table.

Key Points: 
  • At an altitude of 400,000 meters above the earth, the carefully raised marlins would eventually appear on Taikonauts' dinner table.
  • "We are looking forward to see our experimental project would be adopted," Li told the Global Times with excitement.
  • The dream not only provides a solid guarantee for the grand goal of the Chinese path to modernization, but also gives Chinese youth a more imaginative spirit of innovation, and a grander aspiration.
  • "Maybe in one day, I can become a fellow traveler on the dream journey to the sea of stars."

Molecular Assemblies Receives the 2023 BioServices Innovation of the Year Award from BioTech Breakthrough Awards Program

Retrieved on: 
Wednesday, November 8, 2023
Science, Gene editing, Biomedical Research, Molecular biology, Medicine, Biotechnology, Mutagenesis, Protein engineering, Oligonucleotide, Research, NGS, Antibody, Messenger, Molecular assembler, SAN, DNA, Fine chemical, CRISPR

SAN DIEGO, Nov. 8, 2023 /PRNewswire/ -- Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, today announced it has been awarded BioServices Innovation of the Year in the third annual BioTech Breakthrough Awards program, which conducts the industry's most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry. This year's program attracted more than 1,500 nominations from over 12 different countries throughout the world.

Key Points: 
  • "Molecular Assemblies was founded with a vision to deliver long, pure oligonucleotides that power new breakthroughs in biomedical research and beyond," said Larry Stambaugh, Board Chair of Molecular Assemblies.
  • "With our first placements of enzymatically synthesized oligos in customer's hands, this award from BioTech Breakthrough drives home that our vision is now a reality."
  • "We are excited to receive this BioTech Breakthrough Award, which recognizes the companies that have set themselves apart from their competitors," said Phil Paik, Ph.D., Chief Technology Officer of Molecular Assemblies.
  • "Congratulations to Molecular Assemblies for being the 'BioServices Innovation of the Year' winner.

European Parliament Releases Draft Report on the Proposal for the Regulation of Plants Obtained from New Genomic Techniques

Retrieved on: 
Monday, November 6, 2023
Gene editing, Parliament, Commission, Policy, Council, European Commission, International development, Public health, European Parliament Committee on Budgetary Control, Committee, Legislation, Mutagenesis, Transition, NASA Exoplanet Archive, European Parliament, Nature, Civil service commission, Environment, Food safety, Breeding, Plant, CBUS, Commissioner, Council of the European Union, SAN, NGT, European Parliament Committee on the Environment, Public Health and Food Safety, Renewable energy, Agriculture, European, EU

NGTs include a variety of gene editing techniques leading to genetic changes classed as targeted mutagenesis and cisgenesis.

Key Points: 
  • NGTs include a variety of gene editing techniques leading to genetic changes classed as targeted mutagenesis and cisgenesis.
  • The proposal describes a category of NGTs producing modifications that could be obtained in nature or by conventional breeding.
  • The draft report recognizes the Commission proposal as a solid starting point and recommends further improvements to ensure the best possible usage of the techniques in the EU.
  • Source: Draft Report from European Parliament ENVI Committee Rapporteur can be found here via the following link:

Nosh.bio Leverages Ginkgo Strain Optimization Services to Enhance Meaty Taste of Mycoprotein

Retrieved on: 
Monday, October 2, 2023
Taste, DNA, Business development, Partnership, Red meat, Business, Fungus, Protein, Ginkgo Bioworks, Ginkgo, EnCap Investments, Mutagenesis, Entrepreneurship, Meat, Biomass, NYSE, Dietary supplement, Food preservation

Nosh.bio will leverage Ginkgo Strain Optimization Services to screen for protein-producing fungi strains with superior sensorial profiles.

Key Points: 
  • Nosh.bio will leverage Ginkgo Strain Optimization Services to screen for protein-producing fungi strains with superior sensorial profiles.
  • By leveraging Ginkgo's ultra high throughput encapsulated screening capabilities, the program aims to produce a mycoprotein that delivers a rich, savory, and natural meaty taste when used in food products.
  • Using such an improved strain can help Nosh.bio develop a mycoprotein that is superior in taste, color, performance, and nutrition.
  • To learn more about Ginkgo Strain Optimization Services, please visit https://www.ginkgobioworks.com/offerings/strain-optimization-services/ .